Tango Therapeutics is thrilled to announce that it has successfully raised $120 million in its latest funding round—a significant milestone that will drive the company’s mission to discover and develop novel medicines targeting cancer vulnerabilities. Founded in 2017 with a strong Series A investment of $55 million from Third Rock Ventures, Tango has rapidly established itself at the forefront of biotechnology innovation. This recent capital infusion not only underscores investor confidence in Tango’s pioneering approach but also accelerates its commitment to delivering transformational new therapies to patients suffering from cancer.
The new funding will be strategically deployed to further expand Tango’s groundbreaking programs, which focus on exploiting synthetic lethality in cancer cells—a process that targets the unique genetic vulnerabilities of tumors while sparing healthy cells. Tango’s robust product engine leverages state-of-the-art advances in DNA sequencing and CRISPR-based technologies to uncover novel targets and generate breakthrough therapies. Specifically, the funding will bolster research and development efforts across three critical areas: targeting loss of tumor suppressor gene function; addressing multiple oncogenic drivers; and countering cancer’s immune evasion mechanisms, each aimed at well-defined patient populations with limited current treatment options.
By deepening its understanding of the genetic subtypes of cancer, Tango Therapeutics is well-positioned to accelerate the translation of scientific insights into clinical applications. The additional funds will enhance the company’s ability to identify and advance the most promising therapeutic candidates, ultimately leading to more personalized and effective treatments. This investment represents not only a significant vote of confidence in Tango’s innovative strategy, but also a promising step forward in the quest to revolutionize cancer treatment and improve patient outcomes worldwide.
